Xylocor Therapeuticsincis A Privateclinical Stage Biopharmaceutical Company Based In The United Statesthe Company Is Focused On Developing Novel Gene Therapies To Address Advanced Coronary Artery Diseasea Major Health Issue In The U Sxylocor Aims To Enhance The Lives Of Individuals With Cardiovascular Diseases By Advancing Gene Therapy Science The Companyae S Lead Product Candidatexc001Is In Clinical Development For Patients With Ischemic Heart Diseaseparticularly Those Suffering From Refractory Anginaadditionallyxc002 Is A Preclinical Investigational Product Targeting Cardiac Tissue Damage From Heart Attacksxylocor Holds An Exclusive License For Its Gene Therapy Technologies From Weill Cornell Medical Collegeutilizing Proprietary Aav Based Mechanisms To Stimulate The Growth Of New Coronary Blood Vessels In January 2025Xylocor Successfully Raised $67 5 Million In Series B Financing To Further Its Clinical Development Effortsthe Company Is Led By Co Founders Drronald Crystal And Drtodd Rosengartalong With Key Executive Al Gianchettiwho Has Extensive Experience In Drug Development And Commercialization
